ArticleScientific reports2025
Intranasal delivery of blackberry-loaded Chitosan nanoparticles for antipsychotic potential in Ketamine-induced schizophrenia in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Breaking Barriers: Intranasal Microemulsions for the Efficient Nose-to-brain Delivery of Glycyrrhetinic Acid.AAPS PharmSciTech · 2026Article
- Neuroprotective Potential of Free Radical-Scavenging Nanoparticles in Addressing Inflammation and Obesity.IET nanobiotechnology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a neuropsychiatric disorder with limited treatment options that have unwanted side effects. Clozapine, an atypical antipsychotic, has been used for resistant schizophrenia. This study investigated the effect of anthocyanin-rich extract from Rubus fruticosus (RFE) loaded into chitosan nanoparticles against ketamine-induced schizophrenia in rats. The extract's phenolic and flavonoid content was measured using UPLC-ESI-MS/MS, revealing 9.42 ± 0.5 mg of gallic acid equivalent and 2.54 ± 0.02 mg of quercetin equivalent per g of extract, with 19 identified compounds, predominantly anthocyanin glycosides. Chitosan nanoparticles were prepared with chitosan and sodium tripolyphosphate at a ratio of 3:1 with particle size 194.49 ± 5.69 nm and encapsulation efficiency of 64.6 ± 1.12%. Rats were treated with ketamine to induce schizophrenia-like symptoms, and various groups received different treatments, including control, ketamine, ketamine + clozapine, ketamine + RFE, and a combination of clozapine/RFE. Clozapine and RFE treatments were initiated from day 8 to day 14. RFE treatment ameliorated positive, negative, and cognitive symptoms of schizophrenia while mitigating clozapine-induced side effects such as weight gain, hyperglycemia, hyperlipidemia, agranulocytosis, and liver dysfunction. RFE corrected oxidative stress as evidenced by its effect on catalase activity and reduced glutathione level. Additionally, RFE hindered neuroinflammation induced by ketamine and reduced the levels of Tumor Necrosis Factor-α. RFE also increased BDNF levels. This study demonstrates that RFE-loaded chitosan nanoparticles exhibit potent antipsychotic properties and enhance clozapine's therapeutic efficacy while minimizing its adverse effects. This could shed light on the integration of the use of natural products and advanced nano-based formulations to manage schizophrenia patients worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.